A key finding from a European GWAS of lipid levels is the discovery of a causal PCSK9 loss-of-function (LoF) variant (p.Arg46Leu; rs11591147) [8], which has led to the development of PCSK9-inhibitors to treat dyslipidemia [9]. Here, PCSK9 is linked to metabolic syndrome.